熱門資訊> 正文

Regeneron表示，8300万美元收购IPR & D费用对第三季度收入造成负面影响

2025-10-06 19:28

Regeneron Pharmaceuticals (NASDAQ:REGN) said it expects to record an $83 million acquired in-process R&D charge in its third quarter results on a pretax basis, mainly from a previously disclosed $80M upfront payment to Hansoh Pharmaceutical.
The acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the third quarter of 2025 by around $0.68.
Analysts expect $9.62 EPS for the quarter.

More on Regeneron Pharmaceuticals

Regeneron: Growth Catalysts Incoming
Regeneron: Strong R&D Pipeline Drives Growth Outlook
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
FDA won't accept new drug applications during government shutdown
Investment banks weigh in on impact of new pharma tariffs on drugmakers

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。